Fedora Turning Heads with Beta-Lactamase Inhibitors
By Marie Powers
Friday, September 7, 2012
Newly launched Canadian biotech Fedora Pharmaceuticals Inc. has landed in the antibiotics space with multiple beta-lactamase inhibitor candidates in the lead optimization stage of preclinical development and investigational new drug-enabling studies expected to begin next year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.